Best Practices in Oncology Joint Clinical Assessment (JCA) Submissions Under the EU HTA Regulation
August 2026
Real-World Evidence in EU Joint Clinical Assessments: Strategic Use and Methodological Standards
July 2026
Joint Clinical Assessments for Rare Disease Therapies: Lessons from the First EU JCA Experience
June 2026
Integrating Real-World Evidence, Patient-Reported Outcomes, and Equity in Lifecycle HTA: Advancing Dynamic Value Assessment
May 2026
It Takes a Village: Engaging Stakeholders in the Emerging Psychedelics Space
April 2026
How North American Privacy Frameworks Shape Real-World Evidence: A Comparison of Canada and the United States
March 2026
Breaking Barriers in Immuno-Oncology: Mechanistic Insights into Immune Checkpoint Inhibitor (ICI) Resistance and Implications for Health Economics and Outcomes Research (HEOR) and Value Assessment
February 2026
Connecting Biological Pathways with Clinical Outcomes: Developing Conceptual Models
January 2026
The Role Of Real-World Evidence In European HTA For Rare Diseases: Reducing Uncertainty In Reimbursements Decisions
December 2025
Advancing Evidence Generation with External Control Arms: FDA, EMA, and HTA Perspectives
November 2025
Bridging the Gap: How Real-World Evidence (RWE) Is Reshaping HTA Submissions in Emerging & Middle East Markets
October 2025
The Power of Integrated Evidence Generation Plans in Modern Biopharma
September 2025
Introduction to Surrogate Endpoints: From Trial to Treatment Access
August 2025
Advancing Digital Therapeutics: Transforming The Future of Evidence-Based Care
July 2025
Adapting Global Cost-Effectiveness Models: Key Challenges, Recommendations, and Future Directions
June 2025
Advancing Healthcare Decision-Making: Real-World Evidence and Its Role in Regulatory and Health Technology Assessment Submissions
May 2025
Biomarkers: Pathway Toward Targeted Therapy
April 2025
Balancing Efficiency with Accuracy: Artificial Intelligence in Health Economics Outcomes Research
March 2025
From Rare to Recognized: Understanding Orphan Drug Designation in the US & EU
February 2025
More complex than it seems: Determining Disease Incidence and Prevalence
January 2025
From Challenge to Opportunity: Mastering the new EU HTA Landscape
December 2024
